Elobixibat + Placebo oral tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NAFLD
Conditions
NAFLD, NASH
Trial Timeline
Jun 6, 2019 → Jul 15, 2020
NCT ID
NCT04006145About Elobixibat + Placebo oral tablet
Elobixibat + Placebo oral tablet is a phase 2 stage product being developed by Ipsen for NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT04006145. Target conditions include NAFLD, NASH.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006145 | Phase 2 | Completed |
Competing Products
15 competing products in NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Saroglitazar | Zydus Lifesciences | Approved | 85 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Ketohexokinase inhibition | Pfizer | Phase 2 | 51 |
| PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination | Pfizer | Phase 2 | 51 |
| BMS-986036 | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-PNP + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Legalon® 140 mg | Viatris | Pre-clinical | 20 |
| Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg | Ionis Pharmaceuticals | Phase 2 | 49 |
| EDP 305 + Placebo | Enanta Pharmaceuticals | Phase 1 | 25 |